<DOC>
	<DOCNO>NCT01164475</DOCNO>
	<brief_summary>The purpose study compare responses 2 different dos plerixafor patient Non-Hodgkin 's Lymphoma ( NHL ) receive autologous stem cell transplant .</brief_summary>
	<brief_title>Evaluation Approved Weight-Based Dose Compared Fixed Dose Plerixafor Patients With Non-Hodgkin 's Lymphoma ( NHL ) Weighing Less Than 70 Kilograms</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>JM 3100</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Age 18 78 year ( inclusive ) Patients diagnose NHL receive treatment autologous peripheral stem cell transplant first time Biopsyconfirmed diagnosis NHL ( chronic lymphocytic leukemia variant exclude ) Weight le equal 70 kg In first second complete remission partial remission , define purpose study complete partial response follow first secondline therapy At least 4 week since last cycle chemotherapy and/or cancer therapy include rituximab Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 Recovered acute toxic effect prior chemotherapy Negative human immunodeficiency virus ( HIV ) , active hepatitis B , active hepatitis C assessment perform within 3 month sign informed consent Signed informed consent form ( ICF ) White blood cell count ( WBC ) great ( &gt; ) 2.5*10^9 per liter ( L ) Absolute neutrophil count ( ANC ) &gt; 1.5*10^9/L Platelet ( PLT ) count &gt; 100*10^9/L Creatinine clearance &gt; =80 milliliter per minute ( mL/min ) ( estimate CockcroftGault formula 24 hour urine collection ) Serum glutamic oxaloacetic transaminase ( SGOT ) /aspartate aminotransferase ( AST ) , serum glutamic pyruvic transaminase ( SGPT ) /alanine aminotransferase ( ALT ) , total bilirubin le 2.5*upper limit normal Cardiac pulmonary status sufficient undergo apheresis transplantation All patient agree effective method contraception study treatment least 3 month follow plerixafor treatment ( include female patient childbearing potential male patient partner childbearing potential ) A comorbid condition , view Investigator ( ) , render patient high risk treatment complication Failed previous hematopoietic stem cell ( HSC ) collection collection attempt Prior autologous allogeneic transplant Less 6 week 1,3bis ( 2chloroethyl ) 1nitrosourea ( BCNU ) prior first dose GCSF Active central nervous system involvement , active brain metastasis , history carcinomatous meningitis ( active inactive ) Bone marrow involvement &gt; 20 percent ( % ) , assess bone marrow biopsy within 4 month first screen assessment , unless bone marrow biopsy perform immediately prior last chemotherapy negative patient respond last chemotherapy achieve complete partial remission Received radiation therapy pelvis Received granulocyte/macrophagecolony stimulate factor ( GMCSF ) pegfilgrastim within 3 week prior first dose granulocyte colony stimulate factor ( GCSF ) mobilization Received GCSF within 14 day prior first dose GCSF mobilization Received prior radioimmunotherapy ibritumomab tiuxetan tositumomab iodine Active infection , include unexplained fever ( &gt; 38.1 degree Celsius / 100.4 Fahrenheit ) , antibiotic , antiviral , antifungal therapy within 7 day prior first dose GCSF Positive pregnancy test ( female patient ) Lactating ( female patient ) Abnormal electrocardiogram ( ECG ) clinically significant rhythm disturbance ( ventricular arrhythmia ) conduction abnormality last year , opinion Investigator ( ) , warranted exclusion patient trial Previously receive experimental therapy within 4 week enrol currently enrol another experimental protocol G CSF plerixafor treatment period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>78 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>